Article Information
History
- September 29, 2020.
Article Versions
- Version 1 (September 29, 2020 - 05:00).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Shelly Bolotin1,2,3,*,
- Vanessa Tran1,3,
- Selma Osman1,
- Kevin A. Brown1,2,
- Sarah A. Buchan1,2,
- Eugene Joh1,
- Shelley L. Deeks1,2 and
- Vanessa G. Allen1,3
- 1Public Health Ontario, Toronto, Ontario, Canada, M5G 1M1
- 2Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada, M5T 3M7
- 3Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada, M5S 1A8
- ↵*Corresponding author: Shelly Bolotin, 661 University Avenue, 17th floor, Toronto, ON CANADA, M5G 1M1, Telephone: 647 260 7481, Fax: 647 260 7600, Email: shelly.bolotin{at}oahpp.ca
Posted September 29, 2020.
SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline
